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ABSTRACT
Introduction: Bacterial infections that cause
community-acquired urinary tract infections
(CA-UTI) and upper respiratory tract infections
(CA-URTI) are most frequently treated
empirically. However, an increase in
antimicrobial resistance has become a problem
when treating outpatients.
Methods: This study determined the in vitro
activities of oral antibiotics among 1501
pathogens from outpatients with CA-UTI and
CA-URTI in medical centers during 2012 and
2013 from Argentina, Mexico, Venezuela,
Russia, and the Philippines. Minimal
inhibitory concentrations (MICs) were
determined using broth microdilution and
susceptibility defined by Clinical Laboratory
Standards Institute (CLSI) and European
Committee for Antimicrobial Susceptibility
Testing (EUCAST) criteria.
Results: Ceftibuten (MIC50, B0.25 mg/L) was
more potent in vitro compared to other
b-lactams against Enterobacteriaceae from
CA-UTI. Susceptibility to fluoroquinolones using
CLSI criteria varied: Argentina andMexico (50%),
the Philippines (60%), Venezuela (70%), and
Russia (80%). Fosfomycin susceptibility was
[90% against Enterobacteriaceae in each country.
Susceptibility among Enterobacteriaceae to
trimethoprim-sulfamethoxazole was 30.6–75.6%
and nitrofurantoin susceptibility also varied
among the countries and was higher when
EUCAST breakpoints were applied (65–[90%)
compared to CLSI (52–84%). All Haemophilus
influenzae isolates from CA-URTI were
susceptible to ceftibuten, cefixime, cefpodoxime,
and cefuroxime using CLSI breakpoint criteria.
EUCAST criteria produced intermediate and
resistant MIC values for these oral
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cephalosporins. Country-specific susceptibility
variation for fluoroquinolones, macrolides, and
trimethoprim-sulfamethoxazole was observed
among Streptococcus pneumoniae and Streptococcus
pyogenes from CA-URTI.
Conclusion: This study demonstrated that
antimicrobial susceptibility patterns varied in
the five countries investigated among
pathogens from CA-UTI and CA-URTI.
Funding: Merck & Co. Inc., Kenilworth, New
Jersey, USA.
Keywords: Community-acquired UTI and RTI;
Oral antibiotics; Prescribing practices;
Resistance
INTRODUCTION
Antimicrobial pressure, prescribing practices,
and cultural factors, such as drug availability
and cost, produce significant regional
susceptibility differences among certain
bacterial pathogens [1–6]. Individual countries
first-line treatment options differ and may not
be appropriate due to variable resistance
patterns in local environments [2].
Country-specific surveillance data are
available in most regions, but can be
confounding based on the variation of results
obtained from different investigations and
differences in the susceptibility breakpoints
applied in these studies. Regardless,
surveillance studies provide useful information
to primary care physicians who need to
prescribe rational empiric therapy.
Community-acquired urinary tract
infections (CA-UTI) and upper respiratory tract
infections (CA-URTI) are the leading causes of
outpatient infections and the most empirically
treated infections worldwide [1, 6, 7]. Increased
resistance to antibiotics has complicated the
management of both of these outpatient
infections. The spread of Enterobacteriaceae that
carry a chromosomally mediated AmpC
b-lactamase, an extended-spectrum
b-lactamase (ESBL), or a carbapenemase is
becoming a significant concern in the
community [8–11]. Multidrug-resistant
Streptococcus pneumoniae and b-hemolytic
streptococci with tolerance to penicillin and
resistance to macrolides and fluoroquinolones
are increasing in Japan and extreme
drug-resistant S. pneumoniae have been
observed among multidrug-resistant isolates in
Canada [12, 13].
Regional and country variations in pathogen
resistance and the susceptibility breakpoint
differences that are applied must be considered
when determining empiric treatment options
for both CA-UTI and CA-URTI [14, 15]. Many
countries’ adopt or design their own
recommendations of treatment guidelines
based on local surveillance data which can be
scarce in some countries [1–6].
The objective of this study was to
investigate the contemporary pattern of
antimicrobial susceptibility among pathogens
causing CA-UTI and CA-URTI in Argentina,
Mexico, Venezuela, Russia, and the
Philippines. These five countries have limited
local surveillance data available for
understanding susceptibility patterns among
orally prescribed antimicrobial agents for
common outpatient infections.
METHODS
Microbiology laboratories in five countries
which have scare surveillance data were
recruited to collect isolates from
community-acquired infections. Only the first
isolate collected from a patient who was in a
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clinic, a physician’s office, a hospital emergency
room, or in a community hospital for\48 h at
the time of collection was included. Patients
were to have had no prior antibiotic exposure
within the previous 90 days. Bacterial species
from patients with CA-UTI included Escherichia
coli, Klebsiella spp., Proteus mirabilis, and other
less common Enterobacteriaceae. Species from
CA-URTI included S. pneumoniae, Streptococcus
pyogenes, H. influenzae, and M. catarrhalis, and a
limited number of Enterobacteriaceae. A total of
1501 strains were collected during 2012 (29%)
and 2013 (71%) from 12 medical centers,
including two each in Argentina, Mexico,
Venezuela, and the Philippines and four in
Russia.
Identification of the bacterial isolates at the
study site was performed using routine
laboratory procedures and confirmed by
matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) mass
spectrometry (MALDI Biotyper, Microflex,
Bruker Daltonik GmbH, Bremen, Germany) at
a reference laboratory (International Health
Management Associates [IHMA], Schaumburg,
IL, USA). Minimal inhibitory concentrations
(MIC) were determined using the Clinical
Laboratory Standards Institute (CLSI) broth
microdilution procedure and panels prepared
by IHMA using CLSI guidelines [15].
Susceptibility breakpoints used were those
according to the CLSI and European
Committee for Antimicrobial Susceptibility
Testing (EUCAST) guidelines [16, 17]. Applied
EUCAST breakpoints were those utilized for
uncomplicated urinary tract infections which
included amoxicillin-clavulanic acid,
cefuroxime (oral dosing), cefixime,
cefpodoxime, ceftibuten, fosfomycin (oral
dosing), and nitrofurantoin. The oral CLSI
cefuroxime interpretive criteria were used for
Enterobacteriaceae. E. coli ATCC 25922,
Pseudomonas aeruginosa ATCC 27853,
Staphylococcus aureus ATCC 29213, H.
influenzae ATCC 49247, and S. pneumoniae
ATCC 49619 were used as quality control (QC)
strains. The QC MIC ranges utilized were those
of the CLSI [18]. Isolates with an ESBL
phenotype were confirmatory tested using
cefotaxime ± clavulanic acid and
ceftazidime ± clavulanic acid. The
confirmatory test was performed on all E. coli,
Klebsiella pneumoniae, Klebsiella oxytoca, and P.
mirabilis with resistance to cefpodoxime
(MICs[1 mg/L) [18].
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
Among the 960 isolates collected from all
infection sources with a patient age provided,
331 were from pediatric patients and 629 were
from adults (C18 years old). With respect to
patient gender, among the 957 patients with
this information recorded, 601 were female and
356 were male.
Enterobacteriaceae from CA-UTI included 345
isolates of E. coli, 87 K. pneumoniae, 68 P.
mirabilis, 27 Enterobacter cloacae, and 40
isolates of other species. Isolates were obtained
from patients aged 0–17 (n = 76), 18–39
(n = 186), 40–59 (n = 110), 60–79 years
(n = 150), and C80 years (n = 45). Further,
approximately 75% of the isolates were
obtained from women, and 23% of these were
from women aged C65 years. Among the 407
isolates collected from CA-URTI, 64.4% were
collected from pediatric patient infections.
Ceftibuten (MIC50, B0.25 mg/L) was the
most potent oral cephalosporin against
Enterobacteriaceae from CA-UTI in each country
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(Table 1). The difference between the
susceptibility rates of ceftibuten between
countries ranged from 75.2% in the
Philippines to 93.1% in Russia using CLSI
criteria and from 71.7% (the Philippines) to
91.3% (Russia) using EUCAST criteria.
Cefuroxime, cefixime, cefpodoxime, and
cefaclor were less active with a rank order of
potency (MIC50) as follows; cefixime (0.5 mg/
L)[cefpodoxime (0.5–1 mg/L)[cefuroxime
(4–8 mg/L)[cefaclor (4–16 mg/L) and
susceptibility rates lower than ceftibuten in all
countries. Susceptibility to
amoxicillin-clavulanic acid was \60% in all
countries with the exception of Russia
(75.6%). Susceptibility to norfloxacin and
ciprofloxacin was similar and varied from
approximately 50% in Argentina and Mexico,
60% in the Philippines, 70% in Venezuela, and
80% in Russia. Trimethoprim-sulfamethoxazole
susceptibility was highest in Russia (75.6%) and
lowest in Mexico (30.6%). Susceptibility among
E. coli to nitrofurantoin was high (C95%) using
EUCAST breakpoints. However, susceptibility
among combined Enterobacteriaceae species
ranged from 51.5% (Argentina) to 83.3%
(Russia) using CLSI breakpoint criteria. All
Enterobacteriaceae isolated from CA-URTI were
susceptible to fluoroquinolones using CLSI but
\80% using EUCAST breakpoints while
susceptibility percentages ranged from 64% to
79% for the other agents tested using either
CLSI or EUCAST breakpoints (data on file, IHMA
Inc.).
ESBL percentages for E. coli ranged from 9.2%
in Venezuela to 40.7% in Mexico. Similarly,
ESBL percentages for K. pneumoniae were lowest
(18.8%) in Venezuela and highest (46.4%) in
Mexico. ESBL-producing P. mirabilis ranged
from 10% to 33% with the highest percentage
observed in Argentina. Fosfomycin and
nitrofurantoin retained [90% susceptibility
against ESBL-positive E. coli in each country
(data on file, IHMA Inc.). The activity of
fosfomycin and nitrofurantoin diminished
against ESBL-positive K. pneumoniae. Among
the b-lactams tested, ceftibuten and
amoxicillin-clavulanic acid provided the
highest susceptibility percentages.
All H. influenzae isolates were susceptible to
ceftibuten, cefixime, cefpodoxime, and
cefuroxime using CLSI breakpoint criteria
(Table 2). Intermediate and resistant MIC
values were observed for each of these oral
cephalosporins utilizing EUCAST breakpoint
criteria. Reduced activity of
amoxicillin/clavulanic acid was observed
among H. influenzae isolates collected in
Argentina and Mexico. One of three
Haemophilus parainfluenzae from the
Philippines had high-level resistant MIC values
for all tested fluoroquinolones (data on file,
IHMA Inc.). Isolates of M. catarrhalis were only
collected in Argentina and all demonstrated a
common broad spectrum susceptible pattern to
the agents tested.
Streptococcus pneumoniae collected from
Argentina, Mexico, and Russia were more
susceptible to amoxicillin with and without
clavulanic acid compared to other b-lactams
(Table 2). Susceptibility oral cephalosporins
were higher in Argentina compared to Russia
and Mexico. Macrolide susceptibility was
highest in Argentina. Levofloxacin
susceptibility was high in all countries, though
fluoroquinolone-resistant S. pneumoniae isolates
were observed in all countries.
Trimethoprim-sulfamethoxazole susceptibility
was considerably lower in Russia (28–38%)
compared to Mexico (43–57%) and Argentina
(74–85%) dependent upon the applied
breakpoint criteria. All agents had activity
against S. pyogenes. Azithromycin- and
clarithromycin-resistant S. pyogenes was only
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Table 1 Susceptibility rates and MIC values for Enterobacteriaceae collected from CA-UTI
Country (n)/drug CLSI/EUCAST MIC50 MIC90 MIC range
% S % I % R
Argentina (101)
Amoxicillin/clavulanic acid 52.5/82.2 14.9/- 32.7/17.8 8 [32 B1–[32
Ceftibuten 83.2/71.3 3.0/- 13.9/28.7 0.25 [16 B0.06–[16
Ceﬁxime 58.4/58.4 6.9/- 34.7/41.6 0.5 [8 B0.12–[8
Cefpodoxime 56.4/53.5 5.0/- 38.6/46.5 1 [8 B0.12–[8
Cefuroxime 43.6/50.5 13.9/- 42.6/49.5 8 [32 B1–[32
Cefaclor 47.5/NA 6.9/NA 45.5/NA 16 [32 B0.5–[32
Ciproﬂoxacin 50.5/49.5 49.5/1.0 0.0/49.5 1 [1 B0.002–[1
Norﬂoxacin 50.5/38.6 1.98/6.9 47.5/54.5 4 [8 0.03–[8
Fosfomycin 91.1/84.2 1.0/- 7.9/15.8 4 64 B0.25–[128
Nitrofurantoin 51.5/64.4 (100)a 12.9/- 35.6/35.6 32 [128 B2–[128
Trimethoprim/sulfamethoxazole 49.5/49.5 0.0/1.0 50.5/49.5 4 [64 B0.5–[64
Mexico (98)
Amoxicillin/clavulanic acid 58.2/92.9 28.6/- 13.3/7.1 8 32 B1–[32
Ceftibuten 77.6/66.3 6.1/- 16.3/33.7 0.25 [16 B0.06–[16
Ceﬁxime 58.2/58.2 6.1/- 35.7/41.8 0.5 [8 B0.12–[8
Cefpodoxime 60.2/54.1 3.1/- 36.7/45.9 1 [8 B0.12–[8
Cefuroxime 43.9/58.2 16.3/- 39.8/41.8 8 [32 B1–[32
Cefaclor 45.9/NA 7.1/NA 46.9/NA 16 [32 B0.5–[32
Ciproﬂoxacin 51.0/45.9 50.0/5.1 0.0/49.0 1 [1 0.004–[1
Norﬂoxacin 48.0/37.8 6.1/4.1 45.9/58.2 8 [8 0.03–[8
Fosfomycin 95.9/90.8 1.0/- 3.1/9.2 2 32 B0.25–[128
Nitrofurantoin 65.3/80.6 (94.7)c 15.3/- 19.4/19.4 16 [128 B2–[128
Trimethoprim/sulfamethoxazole 30.6/30.6 0.0/3.1 69.4/66.3 [64 [64 B0.5–[64
Venezuela (95)
Amoxicillin/clavulanic acid 55.8/88.4 26.3/- 17.9/11.6 8 [32 B1–[32
Ceftibuten 89.5/84.2 2.1/- 8.4/15.8 0.25 16 B0.06–[16
Ceﬁxime 74.7/74.7 8.4/- 16.8/25.3 0.5 [8 B0.12–[8
Cefpodoxime 82.1/76.8 1.1/- 16.8/23.2 0.5 [8 B0.12–[8
Cefuroxime 52.6/77.9 29.5/- 17.9/22.1 4 [32 B1–[32
Cefaclor 64.2/NA 6.3/NA 29.5/NA 4 [32 B0.5–[32
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Table 1 continued
Country (n)/drug CLSI/EUCAST MIC50 MIC90 MIC range
% S % I % R
Ciproﬂoxacin 72.6/72.6 27.4/0.0 0.0/27.4 0.015 [1 B0.002–[1
Norﬂoxacin 72.6/63.2 0.0/4.2 27.4/32.6 0.12 [8 B0.015–[8
Fosfomycin 92.6/88.4 3.2/- 4.2/11.6 2 64 B0.25–[128
Nitrofurantoin 68.4/81.1 (97.0)c 12.6/- 19.0/19.0 16 128 4–[128
Trimethoprim/sulfamethoxazole 57.9/57.9 0.0/1.1 42.1/41.1 B0.5 [64 B0.5–[64
Russia (160)
Amoxicillin/clavulanic acid 75.6/95.6 15.6/- 8.8/4.4 4 16 B1–[32
Ceftibuten 93.1/91.3 0.6/- 6.3/8.7 0.12 1 B0.06–[16
Ceﬁxime 81.3/81.3 3.1/- 15.6/18.7 0.5 8 B0.12–[8
Cefpodoxime 81.9/80.0 1.2/- 16.9/20.0 0.5 [8 B0.12–[8
Cefuroxime 63.7/79.4 16.9/- 19.4/20.6 4 [32 B1–[32
Cefaclor 76.2/NA 1.9/NA 21.9/NA 4 [32 B0.5–[32
Ciproﬂoxacin 80.0/79.4 20.0/0.6 0.0/20.0 0.015 [1 0.004–[1
Norﬂoxacin 81.9/76.9 0.0/2.5 18.1/20.6 0.06 [8 0.03–[8
Fosfomycin 98.1/95.6 0.6/- 1.3/4.4 1 16 B0.25–[128
Nitrofurantoin 83.8/91.9 (98.4)c 8.1/- 8.1/8.1 16 64 B2–[128
Trimethoprim/sulfamethoxazole 75.6/75.6 0.0/0.6 24.4/23.8 B0.5 [64 B0.5–[64
Philippines (113)
Amoxicillin/clavulanic acid 54.0/84.1 16.8/- 29.2/15.9 8 [32 B1–[32
Ceftibuten 75.2/71.7 7.1/- 17.7/28.3 0.12 [16 B0.06–[16
Ceﬁxime 62.8/62.8 3.5/- 33.6/37.2 0.5 [8 B0.12–[8
Cefpodoxime 67.3/62.8 2.7/- 30.1/37.2 0.5 [8 B0.12–[8
Cefuroxime 48.7/59.3 16.8/- 34.5/40.7 8 [32 B1–[32
Cefaclor 54.0/NA 3.5/NA 42.5/NA 4 [32 B0.5–[32
Ciproﬂoxacin 62.0/59.3 38.1/2.7 0/38.1 0.12 [1 B0.002–[1
Norﬂoxacin 63.7/54.9 8.9/1.8 27.4/43.4 0.5 [8 B0.015–[8
Fosfomycin 91.2/83.2 3.5/- 5.3/16.8 4 64.0 B0.25–[128
Nitrofurantoin 53.1/73.5 (96.3)c 20.4/- 26.6/26.6 32 128.0 B2–[128
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Table 1 continued
Country (n)/drug CLSI/EUCAST MIC50 MIC90 MIC range
% S % I % R
Trimethoprim/sulfamethoxazole 44.3/44.3 0/1.8 55.8/54.0 [64 [64 B0.5–[64
Number in parentheses is the susceptibility rates when applied to E. coli only (EUCAST recommendation)
CLSI Clinical Laboratory Standards Institute, EUCAST European Committee for Antimicrobial Susceptibility Testing, I
intermediate, MIC Minimal inhibitory concentrations, R resistant, S susceptible, CA-UTI community-acquired urinary
tract infection, NA or a dash = No interpretive breakpoints available
Table 2 Susceptibility and MIC values for fastidious respiratory tract pathogens from CA-URTI
Organism Country (n)/drug CLSI/EUCAST MIC50 MIC90
% S % I % R
S. pneumoniae Argentina (19)
Amoxicillin 100/NA 0.0/NA 0.0/NA B0.12 0.25
Amoxicillin/clavulanic acid 100/NA 0.0/NA 0.0/NA B0.12 0.25
Ceftibuten NA/NA NA/NA NA/NA [4 [4
Ceﬁxime NA/NA NA/NA NA/NA 0.25 2
Cefpodoxime 100/94.7 0.0/5.3 0.0/0.0 B0.03 0.25
Cefuroxime 94.7/94.7 5.3/0.0 0.0/5.3 B0.03 0.5
Cefaclor 84.2/0.0 5.3/73.7 10.5/26.3 0.5 4
Azithromycin 78.9/0.0 0.0/78.9 21.1/21.1 B0.5 [4
Clarithromycin 78.9/78.9 0.0/0.0 21.1/21.1 B0.25 [2
Ciproﬂoxacin NA/0.0 NA/100 NA/0.0 0.5 [1
Levoﬂoxacin 94.7/94.7 5.3/0.0 0.0/5.3 2 2
Moxiﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.12 0.12
Doxycycline 84.2/94.7 10.5/0.0 5.3/5.3 B0.06 0.5
Trimethoprim/sulfamethoxazole 73.7/84.2 10.5/0.0 15.8/15.8 0.5 [2
S. pneumoniae Mexico (14)
Amoxicillin 71.4/NA 7.1/NA 21.4/NA B0.12 [16
Amoxicillin/clavulanic acid 71.4/NA 0.0/NA 28.6/NA B0.12 [16
Ceftibuten NA/NA NA/NA NA/NA [4 [4
Ceﬁxime NA/NA NA/NA NA/NA 1 [8
Cefpodoxime 64.3/57.1 0.0/7.1 35.7/35.7 0.12 [4
Cefuroxime 57.1/57.1 14.3/0.0 28.6/42.9 0.25 [4
Cefaclor 28.6/0.0 28.6/21.4 42.9/78.6 2 [8
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Table 2 continued
Organism Country (n)/drug CLSI/EUCAST MIC50 MIC90
% S % I % R
Azithromycin 71.4/0.0 0.0/71.4 28.6/28.6 B0.5 [4
Clarithromycin 71.4/71.4 0.0/0.0 28.6/28.6 B0.25 [2
Ciproﬂoxacin NA/0.0 NA/100 NA/0.0 1 [1
Levoﬂoxacin 85.7/85.7 0.0/0.0 14.3/14.3 2 [16
Moxiﬂoxacin 85.7/85.7 0.0/0.0 14.3/14.3 0.12 [8
Doxycycline 50.0/50.0 0.0/0.0 50/50.0 0.12 [2
Trimethoprim/sulfamethoxazole 42.9/57.1 14.3/0.0 42.9/42.9 1 [2
S. pneumoniae Russia (148)
Amoxicillin 83.8/NA 8.1/NA 8.1/NA B0.12 4
Amoxicillin/clavulanic acid 83.8/NA 6.1/NA 10.1/NA B0.12 [4
Ceftibuten NA/NA NA/NA NA/NA [4 [4
Ceﬁxime NA/NA NA/NA NA/NA 0.5 [8
Cefpodoxime 69.6/67.6 0.7/2.0 29.7/30.4 0.06 [4
Cefuroxime 67.6/65.6 1.3/2.0 31.1/32.4 0.12 [4
Cefaclor 61.5/0.0 3.4/50.7 35.1/49.3 0.5 [8
Azithromycin 56.1/0.0 0.7/56.1 43.2/43.9 B0.5 [4
Clarithromycin 56.8/56.8 0.0/0.0 43.2/43.2 B0.25 [2
Ciproﬂoxacin NA/1.4 NA/98.6 NA/0 0.5 1
Levoﬂoxacin 83.8/87.8 16.2/0.0 0.0/16.2 2 4
Moxiﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.12 0.12
Doxycycline 45.3/49.3 2.7/11.5 52.0/39.2 2 [2
Trimethoprim/sulfamethoxazole 28.4/38.5 24.3/14.2 47.3/47.3 2 [2
S. pyogenes Argentina (20)
Amoxicillin NA/NA NA/NA NA/NA B0.12 B0.12
Amoxicillin/clavulanic acid NA/NA NA/NA NA/NA B0.12 B0.12
Ceftibuten NA/NA NA/NA 0.0/NA 0.5 0.5
Ceﬁxime NA/NA NA/NA NA/NA B0.06 0.12
Cefpodoxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefuroxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefaclor NA/NA NA/NA NA/NA 0.12 0.12
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Table 2 continued
Organism Country (n)/drug CLSI/EUCAST MIC50 MIC90
% S % I % R
Azithromycin 100/0.0 0.0/100 0.0/0.0 B0.5 B0.5
Clarithromycin 100/100 0.0/0.0 0.0/0.0 B0.25 B0.25
Ciproﬂoxacin NA/NA NA/NA NA/NA B0.12 1
Levoﬂoxacin 85.0/75.0 15.0/10.0 0.0/15.0 1 4
Moxiﬂoxacin NA/100 NA/0.0 NA/0.0 B0.06 0.25
Doxycycline NA/95.0 NA/0.0 NA/5.0 B0.06 B0.06
Trimethoprim/sulfamethoxazole NA/100 NA/0.0 NA/0.0 B0.12 B0.12
S. pyogenes Mexico (20)
Amoxicillin NA/NA NA/NA NA/NA B0.12 B0.12
Amoxicillin/clavulanic acid NA/NA NA/NA NA/NA B0.12 B0.12
Ceftibuten NA/NA NA/NA NA/NA 0.25 0.5
Ceﬁxime NA/NA NA/NA NA/NA B0.06 0.12
Cefpodoxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefuroxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefaclor NA/NA NA/NA NA/NA 0.12 0.12
Azithromycin 100/0.0 0.0/100 0.0/0.0 B0.5 B0.5
Clarithromycin 100/100 0.0/0.0 0.0/0.0 B0.25 B0.25
Ciproﬂoxacin NA/NA NA/NA NA/NA B0.12 0.25
Levoﬂoxacin 100/95.0 0.0/5.0 0.0/0.0 1 1
Moxiﬂoxacin NA/100 NA/0.0 NA/0.0 B0.06 0.12
Doxycycline NA/90.0 NA/0 NA/10.0 B0.06 B0.06
Trimethoprim/sulfamethoxazole NA/100 NA/0.0 NA/0.0 B0.12 B0.12
S. pyogenes Philippines (11)
Amoxicillin NA/NA NA/NA NA/NA B0.12 B0.12
Amoxicillin/clavulanic acid NA/NA NA/NA NA/NA B0.12 B0.12
Ceftibuten NA/NA NA/NA NA/NA 0.5 0.5
Ceﬁxime NA/NA NA/NA NA/NA B0.06 0.12
Cefpodoxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefuroxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefaclor NA/NA NA/NA NA/NA 0.12 0.25
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Table 2 continued
Organism Country (n)/drug CLSI/EUCAST MIC50 MIC90
% S % I % R
Azithromycin 81.8/0.0 0.0/81.8 18.2/18.2 B0.5 [4
Clarithromycin 81.8/81.8 0.0/0.0 18.2/18.2 B0.25 [2
Ciproﬂoxacin NA/NA NA/NA NA/NA B0.12 0.25
Levoﬂoxacin 100/90.9 0/9.1 0.0/0.0 1 1
Moxiﬂoxacin NA/100 NA/0.0 NA/0.0 B0.06 0.12
Doxycycline NA/81.8 NA/0.0 NA/18.2 B0.06 [2
Trimethoprim/sulfamethoxazole NA/100 NA/0.0 NA/0.0 B0.12 B0.12
H. inﬂuenzae Argentina (10)
Amoxicillin NA/90.0 NA/0.0 NA/10.0 0.5 2
Amoxicillin/clavulanic acid 90.0/90.0 0.0/0.0 10.0/10.0 1 2
Ceftibuten 100/100 0.0/0.0 0.0/0.0 0.12 0.25
Ceﬁxime 100/100 0.0/0.0 0.0/0.0 B0.015 0.06
Cefpodoxime 100/100 0.0/0.0 0.0/0.0 0.12 0.25
Cefuroxime 100/70.0 0.0/20.0 0.0/10.0 0.5 2
Cefaclor 80.0/0.0 20.0/0.0 0.0/100 4 16
Azithromycin 100/0.0 0.0/100 0.0/0.0 2 2
Clarithromycin 70.0/10.0 30.0/90.0 0.0/0.0 8 16
Ciproﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.008 0.015
Levoﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.03 0.03
Moxiﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.015 0.015
Doxycycline NA/90.0 NA/10.0 NA/0.0 B1 B1
Trimethoprim/sulfamethoxazole 80.0/80.0 0.0/0.0 20.0/20.0 B0.25 [4
H. inﬂuenzae Mexico (12)
Amoxicillin NA/58.3 NA/0 NA/41.7 1 [4
Amoxicillin/clavulanic acid 100/83.3 0.0/0.0 0.0/16.7 1 4
Ceftibuten 100/91.7 0.0/0.0 0.0/8.3 0.12 0.25
Ceﬁxime 100/91.7 0.0/0.0 0.0/8.3 0.03 0.06
Cefpodoxime 100/83.3 0.0/0.0 0.0/16.7 0.25 1
Cefuroxime 100/58.3 0/41.8 0.0/0.0 1 2
Cefaclor 75.0/0.0 16.7/0 8.3/100 4 16
148 Infect Dis Ther (2016) 5:139–153
Table 2 continued
Organism Country (n)/drug CLSI/EUCAST MIC50 MIC90
% S % I % R
Azithromycin 100/0.0 0.0/100 0.0/0.0 2 4
Clarithromycin 66.7/0.0 25/100 8.3/0.0 8 16
Ciproﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.008 0.015
Levoﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.03 0.03
Moxiﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.015 0.015
Doxycycline 0.0/100 0.0/0.0 0.0/0.0 B1 B1
Trimethoprim/sulfamethoxazole 0.0/0.0 0.0/0.0 100/100 [4 [4
H. inﬂuenzae Russia (36)
Amoxicillin NA/94.4 NA/0.0 NA/5.6 0.25 0.5
Amoxicillin/clavulanic acid 100/100 0.0/0.0 0.0/0.0 0.25 0.5
Ceftibuten 100/100 0.0/0.0 0.0/0.0 B0.03 0.06
Ceﬁxime 100/100 0.0/0.0 0.0/0.0 B0.015 0.03
Cefpodoxime 100/100 0.0/0.0 0.0/0.0 B0.03 0.06
Cefuroxime 100/100 0.0/0.0 0.0/0.0 0.25 0.5
Cefaclor 100/0.0 0.0/0.0 0.0/100 2 4
Azithromycin 100/0.0 0/100 0.0/0.0 2 2
Clarithromycin 77.8/2.8 19.4/97.2 2.8/0.0 8 16
Ciproﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.008 0.015
Levoﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.03 0.03
Moxiﬂoxacin 100/100 0.0/0.0 0.0/0.0 B0.008 0.015
Doxycycline 0.0/100 0.0/0.0 0.0/0.0 B1 B1
Trimethoprim/sulfamethoxazole 63.9/63.9 2.8/0.0 33.3/36.1 B0.25 [4
H. inﬂuenzae Philippines (19)
Amoxicillin NA/89.5 NA/0.0 NA/10.5 0.5 4
Amoxicillin/clavulanic acid 100/100 0.0/0.0 0.0/0.0 0.5 0.5
Ceftibuten 100/100 0.0/0.0 0.0/0.0 B0.03 0.06
Ceﬁxime 100/100 0.0/0.0 0.0/0.0 B0.015 0.03
Cefpodoxime 100/100 0.0/0.0 0.0/0.0 0.06 0.12
Cefuroxime 100/84.2 0.0/15.8 0.0/0.0 0.5 2
Cefaclor 100/0.0 0.0/0.0 0.0/100 4 8
Azithromycin 100/0.0 0.0/100 0.0/0.0 2 4
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observed in the Philippines and
fluoroquinolone non-susceptible isolates were
observed in all three countries that submitted S.
pyogenes.
Among the 47 Enterobacteriaceae collected
from CA-URTI using MIC50 values, ceftibuten,
cefixime, and fluoroquinolones had similar
potency (0.03–0.12 lg/mL).
DISCUSSION
This study determined the activity of oral
antimicrobial agents from countries with
limited information on the susceptibility
patterns for pathogens which cause CA-UTI
and CA-URTI. Oral cephalosporins tested in
this study had activity against the majority of
Table 2 continued
Organism Country (n)/drug CLSI/EUCAST MIC50 MIC90
% S % I % R
Clarithromycin 31.6/0.0 68.4/100 0.0/0.0 16 16
Ciproﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.008 0.015
Levoﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.03 0.03
Moxiﬂoxacin 100/100 0.0/0.0 0.0/0.0 0.015 0.03
Doxycycline NA/100 NA/0.0 NA/0.0 B1 B1
Trimethoprim/sulfamethoxazole 31.6/31.6 5.3/0.0 63.2/68.4 [4 [4
M. catarrhalis Argentina (11)
Amoxicillin NA/NA NA/NA NA/NA B0.12 B0.12
Amoxicillin/clavulanic acid 100/100 0.0/0.0 NA/0.0 B0.12 B0.12
Ceftibuten 100/100 0.0/0.0 NA/0.0 B0.03 B0.03
Ceﬁxime NA/NA NA/NA NA/NA B0.03 B0.03
Cefpodoxime NA/NA NA/NA NA/NA 0.5 0.5
Cefuroxime 100/100 0.0/0.0 NA/0.0 B0.12 1
Cefaclor NA/100 NA/0.0 NA/0.0 B0.06 0.12
Azithromycin 100/100 0.0/0.0 0.0/0.0 B0.5 B0.5
Clarithromycin NA/100 NA/0.0 NA/0.0 B0.06 B0.06
Ciproﬂoxacin 63.6/9.1 36.4/9.1 0.0/81.8 B0.25 B0.25
Levoﬂoxacin NA/100 NA/0.0 NA/0.0 B0.06 0.25
Moxiﬂoxacin 100/100 0.0/0.0 NA/0.0 B0.12 B0.12
Doxycycline 100/100 0.0/0.0 0.0/0.0 1 4
Trimethoprim/sulfamethoxazole NA/NA NA/NA NA/NA B0.12 B0.12
CLSI Clinical Laboratory Standards Institute, EUCAST European Committee for Antimicrobial Susceptibility Testing,
I intermediate, MIC minimal inhibitory concentrations, R resistant, S susceptible, CA-URTI community-acquired upper
respiratory tract infection, NA no interpretive breakpoints available
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Enterobacteriaceae. Susceptibility rates were
dependent on the breakpoints that were
applied. Ceftibuten provided the highest and
similar susceptibility rates using either CLSI or
EUCAST breakpoint criteria against CA-UTI
pathogens when compared to the oral
cephalosporins tested. Amoxicillin-clavulanic
acid susceptibility was much lower when using
CLSI breakpoints compared to that observed
using EUCAST uncomplicated UTI breakpoint
criteria for this agent. Country variability in
susceptibility was also observed, even within
the same region with a 20% difference observed
for fluoroquinolone susceptibility among the
Latin American countries examined.
Sites which routinely do not collect
specimens for culture from outpatients with
CA-URTI limited the number of pathogens
collected for this indication and not all
countries provided a representative sample for
this investigation. Also the number of countries
in the three regions studied would not represent
the entire region. Broad spectrum antimicrobial
agents including all of those reported in this
study should be used selectively.
Cephalosporins and fluoroquinolones may not
always be the first choice of therapy; due to the
antibiotic pressure, these and other classes have
on increasing ESBL rates. However, depending
on the source of the infection and the
pharmacokinetic and pharmacodynamics of
the drug class, the loss of activity among other
commonly used oral agents warrants the need
to continue to monitor the viability of oral
cephalosporins and other drugs used for
treating outpatient infections.
It is important that local epidemiology
efforts continue to determine the rate of
emerging or epidemic clones and the
resistance rates among several class agents
which vary based on the susceptibility
breakpoints applied [19–21]. It is equally
important to follow the variation of
prescribing practices and to reduce antibiotic
consumption in the ambulatory setting as this
affects antimicrobial resistance in the hospital
setting [22, 23].
CONCLUSION
Information related to the local and regional
susceptibility patterns of pathogens causing
CA-UTI and CA-URTI is essential for
physicians treating patients with these very
common infections and that was the intent of
this study. Continued surveillance of the
pathogens causing CA-UTI and CA-URTI is
necessary in this era of increasing
antimicrobial resistance. Antimicrobial
stewardship should remain a high priority
across all countries to promote the best
treatment practices to diminish the problem of
antimicrobial resistance.
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